|
Hepatitis, Toxic
|
0.300 |
Therapeutic
|
disease |
CTD_human |
SENP2 alleviates CCl4-induced liver fibrosis by promoting activated hepatic stellate cell apoptosis and reversion.
|
29535048 |
2018 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Therapeutic
|
disease |
CTD_human |
SENP2 alleviates CCl4-induced liver fibrosis by promoting activated hepatic stellate cell apoptosis and reversion.
|
29535048 |
2018 |
|
Drug-Induced Liver Disease
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
SENP2 alleviates CCl4-induced liver fibrosis by promoting activated hepatic stellate cell apoptosis and reversion.
|
29535048 |
2018 |
|
Hepatitis, Drug-Induced
|
0.300 |
Therapeutic
|
disease |
CTD_human |
SENP2 alleviates CCl4-induced liver fibrosis by promoting activated hepatic stellate cell apoptosis and reversion.
|
29535048 |
2018 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Therapeutic
|
disease |
CTD_human |
SENP2 alleviates CCl4-induced liver fibrosis by promoting activated hepatic stellate cell apoptosis and reversion.
|
29535048 |
2018 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Therapeutic
|
disease |
CTD_human |
SENP2 alleviates CCl4-induced liver fibrosis by promoting activated hepatic stellate cell apoptosis and reversion.
|
29535048 |
2018 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Therapeutic
|
disease |
CTD_human |
SENP2 alleviates CCl4-induced liver fibrosis by promoting activated hepatic stellate cell apoptosis and reversion.
|
29535048 |
2018 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Trans-ethnic kidney function association study reveals putative causal genes and effects on kidney-specific disease aetiologies.
|
30604766 |
2019 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Sex-specific and pleiotropic effects underlying kidney function identified from GWAS meta-analysis.
|
31015462 |
2019 |
|
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes.
|
29632382 |
2018 |
|
Electrocardiogram: P-R interval
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
PR interval genome-wide association meta-analysis identifies 50 loci associated with atrial and atrioventricular electrical activity.
|
30046033 |
2018 |
|
Diastolic blood pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation.
|
27841878 |
2017 |
|
Diastolic blood pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk.
|
28135244 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
On the whole, the findings of this study indicate tha SENP2 can act as a tumor suppressor in CLL cells, and may thus prove to be a novel target for CLL treatment in clinical practice.
|
30431078 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Together, these results suggest that SOX9 is a critical downstream effector of the tumor suppressor SENP2 in OS.
|
30542495 |
2018 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Ectopic expression of SENP2 resulted in the suppression of proliferation, migration and invasion in OS cells, whereas SENP2 knockdown by CRISPR-Cas9-based gene editing had the opposite effect.
|
30542495 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Functionally, SENP2 suppresses bladder cancer cell invasion in vitro and tumor metastasis in vivo, acts as a tumor suppressor gene in bladder cancer.
|
28574613 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Thus, our study reveals that SENP2 acts as a tumor suppressor which is deregulated in gastric cancer and the specific de-SUMOylation activity of SENP2 for NDRG2 is critical for it stabilization as well as gastric cancer cells proliferation.
|
29060933 |
2017 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In previous studies, we demonstrated that SENP2 suppresses bladder cancer cell migration and invasion.
|
28574613 |
2017 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
SENP2 appeared to inhibit migration and invasion of bladder cancer cells in vitro, through suppressing MMP13 in BC cells.
|
26369384 |
2015 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Transcriptional analysis of several genes associated with tumor metastasis and invasion demonstrated that SENP2 selectively down-regulated MMP13 in bladder cancer cells.
|
24008762 |
2013 |
|
Malignant neoplasm of breast
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we evaluated the association of SENPs polymorphism with susceptibility as well as clinicopathologic features and patients' response of breast cancer (BC) in a Chinese population.We genotyped SENP1 (rs61918808), SENP2 (rs6762208), SENP7 (rs61697963) by sequencing in a case-control study including 210 BC patients and 225 healthy volunteers.
|
30732133 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
This review will introduce the functions of SENP1 and SENP2 and the underlying signaling pathways in breast cancer for use in discovery of new biomarkers for diagnosis or therapeutic targets for treatment.[BMB Reports 2019; 52(2): 113-118].
|
30638182 |
2019 |
|
Breast Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we evaluated the association of SENPs polymorphism with susceptibility as well as clinicopathologic features and patients' response of breast cancer (BC) in a Chinese population.We genotyped SENP1 (rs61918808), SENP2 (rs6762208), SENP7 (rs61697963) by sequencing in a case-control study including 210 BC patients and 225 healthy volunteers.
|
30732133 |
2019 |